Centaflox®

Composition:

Each ml of Centaflox 0.5% eye drops contains:

Moxifloxacin	0.5% w/v
Hydroxy propyl methyl cellulose	0.025% w/v
Sterile aqueous vehicle	q.s

Pharmacokinetic properties:

Moxifloxacin is readily absorbed from the gastrointestinal tract after oral doses with an absolute bioavailability of about 90%. It is widely distributed throughout the body tissues and is about 30 to 50% bound to plasma proteins. Moxifloxacin has an elimination half-life of about 12 hours, allowing once-daily dosing. It is metabolised mainly via sulfate and glucuronide conjugation, and is excreted in the urine and the faeces as unchanged drug and as metabolites, the sulfate conjugate primarily in the faeces and the glucuronide exclusively in the urine. Distribution into milk has been found in animals.

Mechanism of Action:

Moxifloxacin is a synthetic fluoroquinolone antibacterial agent active *in vitro* against a broad spectrum of Gram-positive and Gram-negative ocular pathogens, atypical microorganisms and anaerobes. The antibacterial action of Moxifloxacin results from inhibition of topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.

HPMC drops are also known as 'artificial tears'. They are used to relieve eye dryness and soreness, particularly when the dryness is caused by a reduced flow of tears. They moisten, soothe and lubricate the surface of your eye, making it feel more comfortable.

Indication:

- In post cataract surgery
- Bacterial conjunctivitis

Contraindication:

Moxifloxacin 0.5% ophthalmic solution is contraindicated in patients with a history of hypersensitivity to Moxifloxacin, to other quinolones, or to any of the components in this medication.

Drug Interaction:

Drug-drug interaction studies have not been conducted with Moxifloxacin 0.5% ophthalmic solution.

Adverse effects:

In clinical trials the most frequently reported ocular adverse events were: decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperaemia, ocular pain, ocular pruritus, subconjunctival haemorrhage, and tearing. These events occurred in approximately 1-6% of patients.

Warnings and Precautions:

NOT FOR INJECTION.
Moxifloxacin 0.5% ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye. In patients receiving systemically administered quinolones, including Moxifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. If an allergic reaction to Moxifloxacin occurs, discontinue use of the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment.

Use in special population:

1. **Pediatric:** The safety and effectiveness of Moxifloxacin 0.5% ophthalmic solution in infants below 1 year of age have not been established.
2. **Geriatric:** No overall differences in safety and effectiveness have been observed between elderly and other adult patients.
3. **Liver impairment:** No data found.
4. **Renal failure:** No data found.
5. **Pregnancy and lactation:** Since there are no adequate and well-controlled studies in pregnant women, Moxifloxacin 0.5% ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Dosage:

Instil one drop in the affected eye 3 times a day for 5 to 7 days.

Presentation:

5ml in plastic bottle.

Storage and handling:

Store at 2°C- 25°C (36°F - 77°F).